Cancer Genetics (CGIX) Posts Quarterly Earnings, Misses Expectations By $0.13 EPS
Cancer Genetics (NASDAQ:CGIX) issued its quarterly earnings data on Thursday. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.37) by $0.13, StockRatingsNetwork reports. The company had revenue of $3.20 million for the quarter, compared to the consensus estimate of $2.13 million.
On a related note, analysts at Cantor Fitzgerald cut their price target on shares of Cancer Genetics from $21.00 to $18.00 in a research note on Friday, May 16th.
Shares of Cancer Genetics (NASDAQ:CGIX) opened at 9.85 on Thursday. Cancer Genetics has a 52-week low of $8.48 and a 52-week high of $23.25. The stock’s 50-day moving average is $10.4 and its 200-day moving average is $13.77. The company’s market cap is $91.4 million.
Cancer Genetics, Inc (NASDAQ:CGIX) is an early-stage, diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.